This website is for US healthcare professionals


Log In to Bolder Science


Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

A Study of Mavacamten in Participants With HFpEF and Chronic Elevation of cTnI and/or NT-proBNP (EMBARK-HFpEF)

  • identifier


  • Recruitment Status


  • First Posted

    February 23, 2021

  • Last update posted

    June 14, 2021

Study Description

Brief summary:

This is a Phase 2a proof-of-concept study to assess safety, tolerability, and preliminary efficacy of mavacamten treatment on biomarkers levels in participants with heart failure with preserved ejection fraction (HFpEF) and chronic elevation of cTnI and/or NT-proBNP. Data from this study will inform future study designs of mavacamten in participants with HFpEF.

  • Condition or Disease:Heart Failure With Preserved Ejection Fraction
  • Intervention/Treatment: Drug: Mavacamten
  • Phase: Phase 2

Detailed Description


Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 35 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: An Exploratory, Open-label, Proof-of-concept, Phase 2a Study of Mavacamten (MYK-461) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Chronic Elevation of Cardiac Troponin I and/or NT-proBNP
  • Actual Study Start Date: March 2021
  • Estimated Primary Completion Date: May 2022
  • Estimated Study Completion Date: May 2022

Arms and interventions

Arm Intervention/treatment
Experimental: Mavacamten (MYK-461)
Drug: Mavacamten
Mavacamten Capsules

Outcome Measures

  • Primary Outcome Measures: 1. Frequency and severity of treatment-emergent adverse events, adverse events of special interest, and serious adverse events. [ Time Frame: 26 weeks ]
  • 2. Mavacamten effect on cTnI levels (at rest) [ Time Frame: 26 weeks ]
    Specifically, change from baseline to Week 26 in cTnI (resting), as assessed by a high-sensitivity assay
  • 3. Mavacamten effect on NT-proBNP levels (at rest) [ Time Frame: 26 weeks ]
    Specifically, change from baseline to Week 26 in NT-proBNP (resting)

Eligibility Criteria

  • Ages Eligible for Study: 50 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No


Key Inclusion Criteria: 1. Is at least 50 years old at Screening. 2. Body weight is greater than 45 kg at Screening. 3. Documented prior objective evidence of heart failure as shown by 1 or more of the following criteria: - Previous hospitalization for heart failure with documented radiographic evidence of pulmonary congestion. - Elevated LV end-diastolic pressure or pulmonary capillary wedge pressure at rest (≥15 mm Hg) or with exercise (≥25 mm Hg). - Elevated level of NT-proBNP (>400 pg/mL) or brain natriuretic peptide (BNP) (>200 pg/mL). - Echocardiographic evidence of medial E/e' ratio ≥ 15 or left atrial enlargement (left atrial volume index >34 mL/m2) together with chronic treatment with spironolactone, eplerenone, or a loop diuretic. 4. Meets 1 or more of the following criteria: - A hs-cTnI >99th percentile at screening OR - NT-proBNP* >300 pg/mL at initial screening measurement (if not in atrial fibrillation or atrial flutter) or >750 pg/mL (if in atrial fibrillation or atrial flutter). OR - If the screened participant is either of African descent or has a body mass index ≥30.0 kg/m2, a screening NT-proBNP* >240 pg/mL (if not in atrial fibrillation or atrial flutter) or >600 pg/mL (if in atrial fibrillation or atrial flutter). 5. Has documented LVEF ≥60% at the Screening visit and no history of prior LVEF ≤ 45% 6. Has documented elevated left ventricular mass index (LVMI) by 2-dimensional imaging (>95 g/m2 if female and >115 g/m2 if male) OR maximal left ventricular wall thickness ≥12 mm. 7. Has adequate acoustic windows on screening resting TTE 8. Has NYHA class II or III symptoms at Screening. Key Exclusion Criteria: 1. Has a prior diagnosis of HCM OR a known infiltrative or storage disorder causing HFpEF and/or cardiac hypertrophy, such as amyloidosis, Fabry disease, or Noonan syndrome with LV hypertrophy OR a positive serum immunofixation result. 2. Has a history of syncope within the last 6 months or sustained ventricular tachycardia with exercise within the past 6 months. 3. Has a history of resuscitated sudden cardiac arrest at any time or known appropriate implantable cardioverter defibrillator discharge within 6 months prior to Screening. 4. Has persistent or permanent atrial fibrillation not on anticoagulation for at least 4 weeks prior to Screening and/or is not adequately rate controlled within 6 months prior to Screening. 5. Currently treated or planned treatment during the study with either: (a) a combination of beta blocker and verapamil or a combination of beta blocker and diltiazem, (b) disopyramide, or (c) biotin or biotin-containing supplements/multivitamins. 6. Has known moderate or severe aortic valve stenosis, hemodynamically significant mitral stenosis, or severe mitral or tricuspid regurgitation at Screening 7. Has severe chronic obstructive pulmonary disease, or other severe pulmonary disease, requiring home oxygen, chronic nebulizer therapy, chronic oral steroid therapy or hospitalized for pulmonary decompensation within 12 months. 8. Has body mass index ≥45.0 kg/m2 9. Has left ventricular global longitudinal strain by TTE in the range from 0 to -12.0 (assessed by central TTE reader) 10. Has NT-proBNP at Screening >2000 pg/mL

Contacts and Locations


Contact: BMS Medical Information Team (Use email contact)

Contact: Myokardia Medical Information Team Study Director


United States, California
Cedars-Sinai Medical Center
Los Angeles

United States, Florida
Jacksonville Center for Clinical Research

United States, Florida
Infinite Clinical Research

United States, Illinois
Northwestern University

United States, Louisiana
Louisiana Heart Center

United States, Michigan
Spectrum Health
Grand Rapids

United States, New York
Weill Cornell Medical Center
New York

United States, North Carolina
Duke University Medical Center

United States, Ohio
The Lindner Center for Research and Education at the Christ Hospital

United States, Oklahoma
South Oklahoma Heart Research
Oklahoma City

United States, Oregon
Providence St. Vincent Medical Center

United States, Oregon
Oregon Health & Science University

United States, Pennsylvania
University of Pennsylvania - Heart and Vascular Center

United States, South Carolina
Medical University of South Carolina (MUSC)

United States, Tennessee
Stern Cardiovascular Foundation, Inc

United States, Utah
University of Utah Hospital & Clinics
Salt Lake City

Sponsors and Collaborators

MyoKardia, Inc.

More Information

  • Responsible Party: MyoKardia, Inc.
  • Identifier: NCT04766892 History of Changes
  • Other Study ID Numbers: MYK-461-019
  • First Posted: February 23, 2021 Key Record Dates
  • Last Update Posted: June 14, 2021
  • Last Verified: June 2021
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Product Manufactured in and Exported from the U.S.: Yes
  • Keywords provided by MyoKardia, Inc.: NT-proBNP
    Cardiac troponin I
  • Additional relevant MeSH terms: Heart Failure